{"id":"https://openalex.org/W4361948835","doi":"https://doi.org/10.1158/1078-0432.c.6517464.v1","title":"Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial","display_name":"Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361948835","doi":"https://doi.org/10.1158/1078-0432.c.6517464.v1"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.c.6517464.v1","doi":"https://doi.org/10.1158/1078-0432.c.6517464.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6517464.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.c.6517464.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018322482","display_name":"ADIL I. DAUD","orcid":"https://orcid.org/0000-0002-6617-8421","observed_orcids":["https://orcid.org/0000-0002-6617-8421"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Adil I. Daud","raw_affiliation_strings":["Hematology/Oncology Division, University of California at San Francisco, San Francisco, California;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology Division, University of California at San Francisco, San Francisco, California;","institution_ids":["https://openalex.org/I180670191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035721135","display_name":"Jana L. Dawson","orcid":"https://orcid.org/0000-0002-4901-0897","observed_orcids":["https://orcid.org/0000-0002-4901-0897"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jana Dawson","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012013052","display_name":"Ronald C. DeConti","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ronald C. DeConti","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064405251","display_name":"Elona Bi\u00e7aku","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Elona Bicaku","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064856723","display_name":"Douglas C. Marchion","orcid":"https://orcid.org/0009-0003-7673-0149","observed_orcids":["https://orcid.org/0009-0003-7673-0149"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas Marchion","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072579867","display_name":"Sem Bastien","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sem Bastien","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074323177","display_name":"Frederick A. Hausheer","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210126566","display_name":"BioNumerik (United States)","ror":"https://ror.org/02yq66p71","country_code":"US","type":"company","lineage":["https://openalex.org/I4210126566"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Frederick A. Hausheer","raw_affiliation_strings":["BioNumerik, Inc., San Antonio, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"BioNumerik, Inc., San Antonio, Texas","institution_ids":["https://openalex.org/I4210126566"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111718623","display_name":"Richard M. Lush","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Lush","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030296219","display_name":"Anthony M. Neuger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony Neuger","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel M. Sullivan","raw_affiliation_strings":["Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Experimental Therapeutics Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida;","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083373965","display_name":"Pamela N. M\u00fcnster","orcid":"https://orcid.org/0000-0002-2074-0984","observed_orcids":["https://orcid.org/0000-0002-2074-0984","https://orcid.org/0009-0009-4141-2312"]},"institutions":[{"id":"https://openalex.org/I180670191","display_name":"University of California, San Francisco","ror":"https://ror.org/043mz5j54","country_code":"US","type":"education","lineage":["https://openalex.org/I180670191"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pamela N. Munster","raw_affiliation_strings":["Hematology/Oncology Division, University of California at San Francisco, San Francisco, California;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hematology/Oncology Division, University of California at San Francisco, San Francisco, California;","institution_ids":["https://openalex.org/I180670191"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9390000104904175,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":0.9390000104904175,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.04969999939203262,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.002400000113993883,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valproic-acid","display_name":"valproic acid","score":0.9869999885559082},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.7960000038146973},{"id":"https://openalex.org/keywords/topoisomerase-i-inhibitor","display_name":"topoisomerase I inhibitor","score":0.9430000185966492},{"id":"https://openalex.org/keywords/histone-deacetylase-inhibitors","display_name":"histone deacetylase inhibitors","score":0.9610000252723694},{"id":"https://openalex.org/keywords/drug-potentiation","display_name":"drug potentiation","score":0.8109999895095825},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.6930000185966492},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8349999785423279},{"id":"https://openalex.org/keywords/dna-strand-breaks","display_name":"DNA strand breaks","score":0.9980000257492065},{"id":"https://openalex.org/keywords/histone-hyperacetylation","display_name":"histone hyperacetylation","score":0.9700000286102295},{"id":"https://openalex.org/keywords/sleepiness","display_name":"sleepiness","score":0.7070000171661377},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8360000252723694},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.8149999976158142}],"concepts":[{"id":"https://openalex.org/C2776202225","wikidata":"https://www.wikidata.org/wiki/Q3569101","display_name":"Histone deacetylase inhibitor","level":5,"score":0.5667820572853088},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.556927502155304},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5015301704406738},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4900180399417877},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4760313332080841},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.47428756952285767},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.4604658782482147},{"id":"https://openalex.org/C147897179","wikidata":"https://www.wikidata.org/wiki/Q407828","display_name":"Topoisomerase","level":3,"score":0.4294165372848511},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3271949291229248},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3109029531478882},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2936956286430359},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.16997477412223816},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.14399081468582153},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08523520827293396},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.07025977969169617}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1078-0432.c.6517464.v1","doi":"https://doi.org/10.1158/1078-0432.c.6517464.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6517464.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.c.6517464.v1","doi":"https://doi.org/10.1158/1078-0432.c.6517464.v1","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.c.6517464.v1","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320311073","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524"},{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337351","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1508389343","https://openalex.org/W1879616740","https://openalex.org/W1917632054","https://openalex.org/W1935102817","https://openalex.org/W1971847818","https://openalex.org/W1985712542","https://openalex.org/W2003907016","https://openalex.org/W2034020928","https://openalex.org/W2034485370","https://openalex.org/W2050931169","https://openalex.org/W2064310618","https://openalex.org/W2092629964","https://openalex.org/W2103665811","https://openalex.org/W2109513968","https://openalex.org/W2114847324","https://openalex.org/W2129938902","https://openalex.org/W2135085078","https://openalex.org/W2135830745","https://openalex.org/W2140985303","https://openalex.org/W2148471976","https://openalex.org/W2160173183","https://openalex.org/W2165455805","https://openalex.org/W2171185186"],"related_works":["https://openalex.org/W2140103101","https://openalex.org/W1156174805","https://openalex.org/W2105590681","https://openalex.org/W2025858622","https://openalex.org/W2044389296","https://openalex.org/W2246142081","https://openalex.org/W2277443631","https://openalex.org/W2129938902","https://openalex.org/W2531464322","https://openalex.org/W2339614040"],"abstract_inverted_index":{"Abstract":[0],"Purpose:":[1],"The":[2,132],"novel":[3],"topoisomerase":[4],"I":[5],"inhibitor":[6],"karenitecin":[7],"(KTN)":[8],"shows":[9],"activity":[10],"against":[11],"melanoma.":[12,37],"We":[13],"examined":[14],"whether":[15],"histone":[16],"deacetylase":[17],"inhibition":[18],"could":[19],"potentiate":[20],"the":[21,29,109,129,153],"DNA":[22,105,196],"strand":[23,106,197],"cleavage,":[24],"cytotoxicity":[25],"as":[26,28,48],"well":[27],"clinical":[30],"toxicity,":[31],"and":[32,42,59,82,97,122,169,175,199],"efficacy":[33],"of":[34,55,72,159,161,231,235],"KTN":[35,60,213],"in":[36,63,92,98,183,229],"Experimental":[38],"Design:":[39],"Apoptosis,":[40],"COMET,":[41],"xenograft":[43],"experiments":[44],"were":[45,115,173],"carried":[46],"out":[47],"described":[49],"previously.":[50],"A":[51],"phase":[52,110],"I/II":[53,111],"trial":[54],"valproic":[56],"acid":[57],"(VPA)":[58],"was":[61,128,138,147,181],"conducted":[62],"patients":[64,114,162],"with":[65,69,117,211,226],"stage":[66],"IV":[67],"melanoma,":[68,221],"any":[70],"number":[71],"prior":[73],"therapies,":[74],"Eastern":[75],"Cooperative":[76],"Oncology":[77],"Group":[78],"performance":[79],"status":[80],"0-2,":[81],"adequate":[83],"organ":[84],"function.":[85],"Results:":[86],"VPA":[87,102,137,146,193,201],"pretreatment":[88],"potentiated":[89],"KTN-induced":[90,104,195],"apoptosis":[91],"multiple":[93],"melanoma":[94],"cell":[95],"lines":[96],"mouse":[99],"A375":[100],"xenografts.":[101],"increased":[103],"breaks.":[107],"In":[108,217],"trial,":[112],"39":[113],"entered,":[116],"37":[118],"evaluable":[119,124],"for":[120,125,136,208],"toxicity":[121],"33":[123],"response.":[126],"Somnolence":[127],"dose-limiting":[130],"toxicity.":[131],"maximum":[133,142,189],"tolerated":[134,143,190],"dose":[135,154],"75":[139,206],"mg/kg/d;":[140],"at":[141,188,205],"dose,":[144],"serum":[145],"\u223c200":[148],"\u03bcg/mL":[149],"(1.28":[150],"mmol/L).":[151],"At":[152],"expansion":[155],"cohort,":[156],"47%":[157,230],"(7":[158],"15)":[160],"had":[163],"stable":[164],"disease;":[165],"median":[166],"overall":[167],"survival":[168],"time":[170],"to":[171],"progression":[172],"32.8":[174],"10.2":[176],"weeks,":[177],"respectively.":[178],"Histone":[179],"hyperacetylation":[180],"observed":[182],"peripheral":[184],"blood":[185],"mononuclear":[186],"cells":[187],"dose.":[191],"Conclusion:":[192],"potentiates":[194],"breaks":[198],"cytotoxicity.":[200],"can":[202],"be":[203],"combined":[204],"mg/kg/d":[207],"5":[209],"days":[210],"full-dose":[212],"without":[214],"overlapping":[215],"toxicities.":[216],"metastatic":[218],"poor":[219],"prognosis":[220],"this":[222,236],"combination":[223,237],"is":[224],"associated":[225],"disease":[227],"stabilization":[228],"patients.":[232],"Further":[233],"testing":[234],"appears":[238],"warranted.":[239]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2023-04-05T00:00:00"}